Patents by Inventor Rolf Spirig

Rolf Spirig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF IMMUNE COMPLEX-MEDIATED KIDNEY DISORDERS
    Publication number: 20220332847
    Abstract: The invention relates to the use of recombinant IgG Fc multimers for the treatment of immune complex-mediated kidney disorders, and methods of treating immune complex-mediated kidney disorders by administering such multimers.
    Type: Application
    Filed: September 11, 2020
    Publication date: October 20, 2022
    Inventors: Helen Zhihui CAO, Rolf SPIRIG, Adrian ZUERCHER, Adriana BAZ MORELLI
  • Treatment and prevention of remote ischemia-reperfusion injury
    Patent number: 10973891
    Abstract: The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: April 13, 2021
    Assignees: CSL Behring GmbH, Universitaet Bern
    Inventors: Rolf Spirig, Sylvia Miescher, Marc Nolte, Claudia Duehrkop-Sisewitsch, Robert Rieben
  • RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA
    Publication number: 20210095006
    Abstract: This disclosure provides the use of recombinant IgG Fc multimers for the treatment of neuromyelitis optica (NMO), and methods of treating NMO by administering such multimers.
    Type: Application
    Filed: December 14, 2018
    Publication date: April 1, 2021
    Inventors: Rolf SPIRIG, Adriana BAZ MORELLI, Alan VERKMAN, Lukmanee TRADTRANTIP
  • TREATMENT AND PREVENTION OF REMOTE ISCHEMIA-REPERFUSION INJURY
    Publication number: 20190269766
    Abstract: The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 5, 2019
    Inventors: Rolf SPIRIG, Sylvia MIESCHER, Marc NOLTE, Claudia DUEHRKOP-SISEWITSCH, Robert RIEBEN
  • Treatment and prevention of remote ischemia-reperfusion injury
    Patent number: 10286047
    Abstract: The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: May 14, 2019
    Assignees: CSL Behring GmbH, Universität Bern
    Inventors: Rolf Spirig, Sylvia Miescher, Marc Nolte, Claudia Duehrkop-Sisewitsch, Robert Rieben
  • RECOMBINANT IGG FC MULTIMERS
    Publication number: 20190119377
    Abstract: This disclosure provides recombinant IgG Fc multimers and methods of treating autoimmune and inflammatory diseases by administering such multimers.
    Type: Application
    Filed: January 27, 2017
    Publication date: April 25, 2019
    Inventors: Rolf SPIRIG, Fabian KAESERMANN, Adrian ZUERCHER, Con PANOUSIS, Adriana BAZ MORELLI, Chao-Guang CHEN
  • Sugar compositions for treating hemophilia A and/or Von Willebrand disease
    Patent number: 10232015
    Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: March 19, 2019
    Assignee: CSL BEHRING GMBH
    Inventors: Stefan Schulte, Rolf Spirig, Sabine Zollner, Michael Moses, Wilfried Wormsbaecher, Hans-Arnold Stoehr
  • Sugar Compositions for Treating Hemophilia A and/or Von Willebrand Disease
    Publication number: 20170274045
    Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.
    Type: Application
    Filed: June 14, 2017
    Publication date: September 28, 2017
    Applicant: CSL Behring GmbH
    Inventors: Stefan SCHULTE, Rolf SPIRIG, Sabine ZOLLNER, Michael MOSES, Wilfried WORMSBAECHER, Hans-Arnold STOEHR
  • Sugar compositions for treating hemophilia A and/or von Willebrand disease
    Patent number: 9707269
    Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 18, 2017
    Assignee: CSL BEHRING GMBH
    Inventors: Stefan Schulte, Rolf Spirig, Sabine Zollner, Michael Moses, Wilfried Wormsbaecher, Hans-Arnold Stoehr
  • TREATMENT AND PREVENTION OF REMOTE ISCHEMIA-REPERFUSION INJURY
    Publication number: 20160008442
    Abstract: The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitor to an individual.
    Type: Application
    Filed: March 7, 2014
    Publication date: January 14, 2016
    Inventors: Rolf SPIRIG, Sylvia MIESCHER, Marc NOLTE, Claudia DUEHRKOP-SISEWITSCH, Robert RIEBEN
  • Sugar Compositions for Treating Hemophilia A and/or Von Willebrand Disease
    Publication number: 20150087592
    Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 26, 2015
    Applicant: CSL Behring GmbH
    Inventors: Stefan Schulte, Rolf Spirig, Sabine Zollner, Michael Moses, Wilfried Wormsbaecher, Hans-Arnold Stoehr